Search Results - "Lu, Janice M."

Serum phosphatidylcholine is lower among breast cancer patients on systemic chemotherapy by Li, Xin, Lim, John, Kolatkar, Anand, Welter, Lisa, Waitman, Kathryn, Hwang, Eun-Sil Shelley, Lu, Janice M., Kuhn, Peter, Nieva, Jorge J.

“…Abstract only e12571 Background: Chemotherapy-induced cognitive impairment, also known as 'chemobrain', is widely recognized as a frequent adverse effect of…”
Get full text

Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study by Hochster, Howard, Chen, Thomas T, Lu, Janice M, Hills, Day, Sorich, Joan, Escalon, Juliet, Ivy, Percy, Liebes, Leonard, Muggia, Franco

“…Abstract Background. Topotecan 14-day infusion combined with cisplatin was highly active in ovarian cancer, but too myelosuppressive. We therefore sought to…”
Get full text

Emerging treatments for ovarian cancer by Muggia, Franco, Lu, M Janice

“…The survival at 5 years, of patients with ovarian cancer, has steadily improved since 1960, when surgery and alkylating agents were the only initial modalities…”
Get more information

Interplay between B cell and GABA metabolism (GABAm) and association with immune evasion in breast carcinoma (BC) by Chow, Frances Elaine, Kang, Irene, Yin, Jun, Farrell, Alex, Martirosian, Vahan, Jayachandran, Priya, Roussos Torres, Evanthia T., Lu, Janice M., Lenz, Heinz-Josef, Ma, Cynthia X., McArthur, Heather L., Basho, Reva K, Spetzler, David, Neman, Josh

“…1097 Background: GABAergic signaling has been reported to play a pivotal role in breast cancer (BC) tumorigenesis and metastasis, however, its role in immune…”
Get full text

Is there a role for 21-gene recurrence score in mucinous carcinoma of breast? by Yap, Kelly Khai Li, Koc, Melissa, Lu, Janice M., Spicer, Darcy V.

“…Abstract only…”
Get full text

Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer by Kang, Irene, Spicer, Darcy V., Lu, Janice M., Groshen, Susan G., Tsao-Wei, Denice, Garcia, Agustin A.

“…Abstract only e12508 Background: Metronomic chemotherapy is an emerging paradigm of cancer therapy in which low doses of chemotherapy are delivered at frequent…”
Get full text

Comprehensive characterization of androgen receptor expression in breast cancer by Jayachandran, Priya, Deshmukh, Sachin, Wu, Sharon, Enriquez, Kathryn Therese, Kang, Irene, Xiu, Joanne, Farrell, Alex Patrick, Battaglin, Francesca, Mittal, Pooja, Lu, Janice M., Soni, Shivani, Zhang, Wu, Millstein, Joshua, Ma, Cynthia X., Graff, Stephanie L., Radovich, Milan, Lenz, Heinz-Josef, Spicer, Darcy V., Sledge, George W., Roussos Torres, Evanthia T.

“…1035 Background: The androgen receptor ( AR) is a hormone-regulated transcription factor that plays an important role in breast cancer (BC) pathogenesis. While…”
Get full text

Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens by Lu, Janice M., Kalinsky, Kevin, Tripathy, Debu, Sledge, George W., Gradishar, William John, O'Regan, Ruth, O'Shaughnessy, Joyce, Modi, Shanu, Park, Haeseong, McCartney, Amelia, Frentzas, Sophia, Shannon, Catherine M., Eek, Richard Wilhelm, Martin, Miguel, Curigliano, Giuseppe, Jerusalem, Guy Heinrich Maria, Huang, Chiun-Sheng, Press, Michael F., Tolaney, Sara M., Hurvitz, Sara A.

“…TPS1112 Background: The overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) occurs in approximately 20% of breast cancers…”
Get full text

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC) by Kaklamani, Virginia G., Bardia, Aditya, Aftimos, Philippe Georges, Cortes, Javier, Lu, Janice M., Neven, Patrick, Streich, Guillermo, Montero, Alberto J., Forget, Frederic, Mouret-Reynier, Marie-Ange, Sohn, Joohyuk, Taylor, Donatienne, Harnden, Kathleen Kiernan, Khong, Hung T., Kocsis, Judit, Dalenc, Florence, Dillon, Patrick Michael, Tonini, Giulia, Grzegorzewski, Kris, Bidard, François-Clement

“…1100 Background: EMERALD demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for elacestrant vs standard of…”
Get full text

Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC) by Wesolowski, Robert, Pathan, Nuzhat, Zhu, Zhou, Stringer-Reasor, Erica Michelle, Han, Hyo S., Dees, Elizabeth Claire, Bardia, Aditya, Layman, Rachel M., Weise, Amy, Kabos, Peter, Lu, Janice M., Kern, Kenneth Alan, Pierce, Kristen J., Rugo, Hope S.

“…Abstract only 1052 Background: Endocrine therapy with a CDK4/6 inhibitor (CDKi) is standard of care (SOC) for patients (pts) with estrogen-receptor-positive…”
Get full text

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer by Tiu-lim, Justin Wayne Wong, Yin, Jun, Xiu, Joanne, Korn, Wolfgang Michael, Lenz, Heinz-Josef, In, Gino Kim, Roussos Torres, Evanthia T., Lu, Janice M., Spicer, Darcy V., Xia, Bing, Hoon, Dave S. B., Krill-Jackson, Elisa, Heeke, Arielle Lutterman, Sammons, Sarah, Isaacs, Claudine, Ademuyiwa, Foluso Olabisi, Ma, Cynthia X., Tan, Antoinette R., Kang, Irene

“…Abstract only 1034 Background: The Ras-MAPK pathway is a known driver of tumorigenesis and therapeutic target in a variety of cancers. Alterations in this…”
Get full text

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials by Hurvitz, Sara A., Park, Haeseong, Frentzas, Sophia, Shannon, Catherine M., Cuff, Katharine, Eek, Richard Wilhelm, Budd, George Thomas, McCartney, Amelia, O'Shaughnessy, Joyce, Lu, Janice M., Zhang, Jian, Ji, Dongmei, Shen, Weina, Li, Matt, Yan, Jinchun, Xia, Gang, Ji, Yanping, Yao, Sulan, Xiong, Gaozhun, Hu, Xichun

“…Abstract only 1038 Background: ARX788 is a site-specific, homogeneous, and highly stable ADC. The payload AS269 is conjugated to the synthetic amino acids…”
Get full text

Review of next generation sequencing outcomes in patients with metastatic breast cancer by Kang, Irene, D'souza, Anishka, Spicer, Darcy V., Russell, Christy Ann, Lang, Julie E., Nelson, Maria, Silberman, Howard, Lu, Janice M.

“…Abstract only e12558 Background: Among patients with newly diagnosed breast cancer in the US, 6-10% will have metastatic disease. With many treatment options…”
Get full text

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy by Lu, M Janice, Sorich, Joan, Hazarika, Maitreyee, Kim, Mimi, Del Priore, Giuseppe, Jacobs, Allan J, Chiang, Chang, Liu, Paul C, Fusco, Eileen, Curtin, John P, Muggia, Franco M

“…Although three large phase III trials have documented the benefit of IP chemotherapy, this therapy as consolidation has been studied in only a few pilot…”
Get more information

Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC) by DeLaurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Bofill, Salvador, Jacot, William, Dent, Susan Faye, Martin, Miguel, Ring, Alistair E., Cottu, Paul H., Lu, Janice M., Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Ankrah, Nii, Zamagni, Claudio

“…Abstract only 1041 Background: RIBO, an oral, selective inhibitor of CDK4/6 (CDK4/6i), is approved for use in combination with endocrine therapy (ET) in women…”
Get full text

Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC) by De Laurentiis, Michelino, Borstnar, Simona, Campone, Mario, Warner, Ellen, Salvador Bofill, Javier, Jacot, William, Dent, Susan Faye, Martin, Miguel, Ring, Alistair E., Cottu, Paul H., Lu, Janice M., Ciruelos, Eva, Azim, Hamdy A., Chatterjee, Sanjoy, Zhou, Katie, Wu, Jiwen, Ankrah, Nii, Zamagni, Claudio

“…Abstract only 1055 Background: Real-world evidence is important as it complements data from randomized controlled trialse report updated results from…”
Get full text

Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009) by Forero-Torres, Andres, Han, Heather, Dees, Elizabeth Claire, Wesolowski, Robert, Bardia, Aditya, Kabos, Peter, Layman, Rachel M., Lu, Janice M., Kern, Kenneth Alan, Perea, Rachelle, Pierce, Kristen J., Houk, Brett, Pathan, Nuzhat, Rugo, Hope S.

“…Abstract only…”
Get full text

Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib by D'souza, Anishka, Shishedo, Stephanie, Spicer, Darcy V., Welter, Lisa, Jiang, Yuanfei, Hyman, David Michael, Solit, David B., Ma, Cynthia X., Bose, Ron, Cutler, Richard E., Eli, Lisa, Hicks, James B, Kuhn, Peter, Lu, Janice M.

“…Abstract only e12554 Background: ERBB2 mutations in the absence of gene amplification are rare, with an incidence of 2-4%. Neratinib is a HER2/EGFR tyrosine…”
Get full text

Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial by DeLaurentiis, Michelino, Neven, Patrick, Jerusalem, Guy Heinrich Maria, Bachelot, Thomas Denis, Jacot, William, Dent, Susan Faye, Colleoni, Marco, Prat, Aleix, Martin, Miguel, Ring, Alistair E., Cottu, Paul H., Lu, Janice M., Azim, Hamdy A., Zhou, Katie, Wu, Jiwen, Zarate, Juan Pablo, Zamagni, Claudio

“…Abstract only…”
Get full text

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis by Wu, Shenhong, Dr, Chen, John J, PhD, Kudelka, Andrzej, MD, Lu, Janice, MD, Zhu, Xiaolei, MD

“…Summary Background Sorafenib is used in patients with advanced renal-cell carcinoma (RCC) or hepatocellular cancer, and its application in other types of…”
Get full text